lipolysis 英 /lɪ'pɒlɪsɪs/
释 义 n. 脂类分解；[生化] 脂解作用
例 句 The treatment is a form ofnon-invasive, laser-assisted fat-removal, or lipolysis.这是一种非侵入性、激光辅助消除脂肪或分解脂类的疗法。
作者： Park JH
期刊：J Pineal Res
Sodium glucose cotransporter 2 inhibitors (SGLT2i) are a new class of effective hypoglycemic agents that can be used to treat type 2 diabetes (T2D) by suppressing glucose reabsorption in the kidney. SGLT2i exert additional beneficial effects on obesity and hypertension. However, SGLT2i might raise the risk of diabetic ketoacidosis (DKA), including euglycemic DKA, and the risk of DKA is higher with SGLT2i treatment than with other glucose-lowering agents such as DPP4 inhibitors. DKA is an acute and fatal complication of diabetes and therapeutic management of DKA includes fluid replacement for electrolyte balance and insulin infusion. However, there are no clear preventive agents for DKA. Furthermore, euglycemic DKA could lead to delayed diagnosis and treatment because of the normal blood glucose level, and this can accelerate progressive metabolic deterioration. Therefore, even though the incidence of euglycemic DKA development associated with SGLT2i in T2D is low, it is important to develop a therapeutic or preventive agent for SGLT2i-induced euglycemic ketoacidosis. Mechanisms for euglycemic DKA associated SGLT2i have been proposed, including hypoinsulinemia due to decreased blood glucose levels and increases in insulin counter-regulatory hormones (glucagon, corticosterone, and growth hormone) due to reduction of insulin secretion. It has also been reported that SGLT2i can increase plasma corticosterone and catecholamine concentrations due to osmotic diuresisinduced hypovolemia. All of these systemic changes induced by SGLT2i could stimulate white adipose tissue (WAT) lipolysis and hepatic ketogenesis, resulting in euglycemic DKA. SGLT2i induce glycosuria, which can decrease blood glucose levels, resulting in euglycemic DKA. Moreover, SGLT2i can also induce mild insulin deficiency and improve insulin resistance, resulting in euglycemic DKA.